✦ LIBER ✦

Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

✍ Scribed by Massard, Christophe; Margetts, Jane; Amellal, Nadia; Drew, Yvette; Bahleda, Ratislav; Stephens, Peter; Armand, Jean Pierre; Calvert, Hilary; Soria, Jean Charles; Coronado, Cinthya; Kahatt, Carmen; Alfaro, Vicente; Siguero, Mariano; Fernández-Teruel, Carlos; Plummer, Ruth

Book ID: 121637912
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 49 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-9954-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of PM00104 (Zalypsis®) adm

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

✍ Massard, Christophe; Margetts, Jane; Amellal, Nadia; Drew, Yvette; Bahleda, Rati 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 171 KB

A phase I pharmacokinetic study of PM001

A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors

✍ J. Capdevila, S. Clive, E. Casado, C. Michie… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 274 KB

179 POSTER Phase I study of the novel an

179 POSTER Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma

✍ J.C. Soria; R. Plummer; A. Soto; C. Massard; H. Calvert; R. Prados; E. Angevin; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 62 KB

550 Phase I and pharmacokinetic (PK) stu

550 Phase I and pharmacokinetic (PK) study of trabectedin (ET-743) administered as a 1-hour infusion weekly for 3 consecutive weeks every 4 weeks to patients with advanced cancer

✍ S.Q. Chu; G. Schwartz; M. Beeram; A. Patniak; M. Mita; J. Jimeno; L. Lopez-Laraz 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 273 KB

A phase I and pharmacokinetic study of D

A phase I and pharmacokinetic study of DE-310 administered as a 3 hour infusion every 4 weeks (wks) to patients (pts) with advanced solid tumors or lymphomas

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Phase I dose-escalating study of ES-285

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

✍ C. Massard, R. Salazar, J. P. Armand, M. Majem, E. Deutsch, M. García, A. Oaknin 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 591 KB